Skip to main content

Dr. Farhad Rafii, M.D.

Cardiology (Cardiovascular Disease Physician)

7301 Medical Center Dr Ste 201
West Hills, CA 91307

Who else practices at this address →

Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas

Call (818) 702-8800

  • Medicare participating

At a glance

Years since graduation
19
In the NPI registry since
2008
Medicare patients seen, 2024
1,181

Licensed in California since 2008, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Medical school: University of Southern California Keck School of Medicine
  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Cardiovascular Disease Physician primary
    CA license A105505 (first issued 2008; current)
  • Internal Medicine Physician
    CA license A105505 (first issued 2008; current)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Cardiology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,181
Services billed
12,804
Patients’ average age
77
Most frequent Medicare services, 2023
ServiceTimesPatients
Management using the results of remote vital sign monitoring per calendar month, first 20 minutes2,535318
Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days2,082290
Established patient office or other outpatient visit, 30-39 minutes1,294643
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes996259
Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes640221
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report466377
Ultrasound of heart with color-depicted blood flow, rate, direction and valve function403384
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes260221
Blood test, clotting time17513
Injection, regadenoson, 0.1 mg16842

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 19 companies reported 119 payments worth $5,475 in total to this clinician.

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 21, 2025Novartis Pharmaceuticals Corporation
Nov 21, 2025
Consulting Fee$2,356
Aug 28, 2025Medtronic, Inc.
Aug 28, 2025
Travel and Lodging
EVERA MRI XT DR SURESCAN · Implantable Cardioverter Defibrillators (ICDs) · travel to Minneapolis, MN · in-kind
$431

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 13 industry-funded studies in 2025, from 6 companies. The companies reported $673,077 in research payments for these studies, mostly to the institutions running them.

  • A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
    Eli Lilly and Company · Active, not recruiting · NCT06292013
  • A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
    Novartis Pharmaceuticals Corporation
  • Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
    Novartis Pharmaceuticals Corporation
  • A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and…
    AstraZeneca UK Limited
  • Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENT…
    Novartis Pharmaceuticals Corporation
  • REDEFINE-HF Study #22438
    Bayer HealthCare Pharmaceuticals Inc.
  • Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
    Alnylam Pharmaceuticals Inc.
  • A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
    Novartis Pharmaceuticals Corporation
  • BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV…
    Bayer HealthCare Pharmaceuticals Inc.
  • A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascula…
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Cardiology clinicians in West Hills

Sources

NPI registry (CMS NPPES, November 2026; record last updated June 14, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1740433705. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.